Assessing Biological Aging in a Real-World Medical Weight Loss Program Using the LinAge2 Clinical Clock

NCT07444073 | Not Yet Recruiting

• 1 other identifier: NUS-IRB-2025-845
• Study Type: observational
• Target: 440
• Locations: 1 country
• Sites: 2

Brief Summary

This study examines whether routine treatment with semaglutide or tirzepatide, prescribed with lifestyle coaching in a real-world weight-management program, is associated with changes in biological age measured by the LinAge2 clinical aging clock over 6 months.

Conditions

Aging; Obesity & Overweight

Keywords

LinAge2; Biological Age; GLP-1 Receptor Agonist; Semaglutide; Tirzepatide; Weight Management Program; Lifestyle; Real-World Evidence; Cardiometabolic Biomarkers; Body Composition; Prospective Cohort

Outcome Measures

Primary Outcomes (1)

• LinAge2 Biological Age

  The primary outcome of this study is to determine the change in LinAge2 biological age estimates in response to the NOVI Health weight management program, which comprises GLP-1 RA therapy alongside personalized diet and physical activity interventions.

  Baseline and 6 months

Secondary Outcomes (30)

• Change in Body Composition: Body Weight

  Baseline and 6 months

• Change in Body Composition: Body Mass Index (BMI)

  Baseline and 6 months

• Change in Body Composition: Waist Circumference

  Baseline and 6 months

• Change in Body Composition: Hip Circumference

  Baseline and 6 months

• Change in Body Composition: Waist-to-Hip Ratio

  Baseline and 6 months

Study Arms (1)

NOVI Health weight management cohort

Adults newly enrolled in the NOVI Health weight management program receiving standard-of-care GLP-1 receptor agonist therapy (semaglutide or tirzepatide) and lifestyle coaching (diet and physical activity) as part of routine clinical care. Medication type is determined by routine clinical care and patient-clinician decision-making, not by the research study.

Other: Not applicable. This is an observational study.

Interventions

Not applicable. This is an observational study. OTHER

Not applicable. This is an observational study.

NOVI Health weight management cohort

Eligibility Criteria

• Age: 40 Years - 89 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Adults aged 40-89 years who are overweight or obese and newly enrolled in the NOVI Health weight management program in Singapore. Participants are selected from routine clinical practice at the NOVI Health clinic.

You may qualify if:

• Adults aged 40-89 years, who are newly enrolled in the NOVI OP+ weight management program.
• BMI of ≥ 27.5 kg/m2 (if Asian) or 30 kg/m2 (if non-Asian); OR
• BMI of ≥ 23 kg/m2 (if Asian) / 25 (if non-Asian) kg/m2 in the presence of a weight-related chronic condition (e.g., diabetes, pre-diabetes, polycystic ovarian syndrome, hypertension, fatty liver, high cholesterol).

You may not qualify if:

• Pregnancy or lactation.
• Non-ambulatory status, total blindness, complete hearing loss, or inability to speak.
• Medical history of, or self-reported, psychiatric illness, congenital or irreversible neurodegenerative diseases, cognitive impairment, or eating disorders that may affect adherence or assessment outcomes.
• Concomitant anti-diabetic therapy.
• Active cancer on chemotherapy or immunotherapy.
• Known hypersensitivity or contraindications to GLP-1 RAs.
• Any condition, in the opinion of the attending clinician, that would jeopardize participant safety or interfere with study compliance.

Sponsors & Collaborators

• National University of Singapore: lead
• T3 Health PTE LTD: collaborator

Study Sites (2)

NOVI Health (T3 Health PTE LTD)

Singapore, 068914, Singapore

Location

National University of Singapore

Singapore, 119077, Singapore

Location

Related Publications (1)

• Fong S, Pabis K, Latumalea D, Dugersuren N, Unfried M, Tolwinski N, Kennedy B, Gruber J. Principal component-based clinical aging clocks identify signatures of healthy aging and targets for clinical intervention. Nat Aging. 2024 Aug;4(8):1137-1152. doi: 10.1038/s43587-024-00646-8. Epub 2024 Jun 19.

  PMID: 38898237 BACKGROUND

Related Links

• LinAge2 clinical aging clock

MeSH Terms

Conditions

Obesity; Overweight

Condition Hierarchy (Ancestors)

Overnutrition; Nutrition Disorders; Nutritional and Metabolic Diseases; Body Weight; Signs and Symptoms; Pathological Conditions, Signs and Symptoms

Study Officials

• Jan Gruber, PhD

  National University of Singapore

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Zhi Meng Lim, MSc

CONTACT

+65 90084510; zmlim@nus.edu.sg

Hui Ching Michelle Lee, PhD

CONTACT

michelle.lee@novi-health.com

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Associate Professor

Study Record Dates

• First Submitted: February 12, 2026
• First Posted: March 2, 2026
• Study Start: February 2, 2026
• Primary Completion (Estimated): December 31, 2026
• Study Completion (Estimated): December 31, 2026
• Last Updated: March 2, 2026

Record last verified: 2026-02

Locations

SG (2)